Showing results (21-30 of 40) with videos related to
Sort By:
Pageof 4
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 19, 2018
NOTCH1 Represses MCL-1 Levels in GSI-resistant T-ALL, Making them Susceptible to ABT-263Anahita Dastur, AHyun Choi, Carlotta Costa, et al.Developmental Cell|April 5, 2014
PI3K class II α controls spatially restricted endosomal PtdIns3P and Rab11 activation to promote primary cilium functionIrene Franco, Federico Gulluni, Carlo C Campa, et al.Proceedings of the National Academy of Sciences of the United States of America|April 22, 2026
Targeting CRTC2 reverses STK11 mutant NSCLC tumor resistance to immunotherapyDimitri Robay, Ole Ackermann, Laurent Laborde, et al.Cancer Cell|July 9, 2014
CDK 4/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitorsSadhna R Vora, Dejan Juric, Nayoon Kim, et al.Science Signaling|September 11, 2008
Phosphoinositide 3-kinase p110beta activity: key role in metabolism and mammary gland cancer but not developmentElisa Ciraolo, Manuela Iezzi, Romina Marone, et al.PNAS Nexus|January 30, 2023
Genomic screening reveals ubiquitin-like modifier activating enzyme 1 as a potent and druggable target in c-MYC-high triple negative breast cancer modelsSheeba Jacob, Tia H Turner, Jinyang Cai, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 10, 2017
Venetoclax Is Effective in Small-Cell Lung Cancers with High BCL-2 ExpressionTimothy L Lochmann, Konstantinos V Floros, Mitra Naseri, et al.Cancer Discovery|October 29, 2013
mTOR inhibition specifically sensitizes colorectal cancers with KRAS or BRAF mutations to BCL-2/BCL-XL inhibition by suppressing MCL-1Anthony C Faber, Erin M Coffee, Carlotta Costa, et al.Cancer Discovery|October 10, 2019
PTEN Loss Mediates Clinical Cross-Resistance to CDK4/6 and PI3Kα Inhibitors in Breast CancerCarlotta Costa, Ye Wang, Amy Ly, et al.Proceedings of the National Academy of Sciences of the United States of America|February 25, 2018
Coamplification of miR-4728 protects HER2-amplified breast cancers from targeted therapyKonstantinos V Floros, Timothy L Lochmann, Bin Hu, et al.Pageof 4